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Abstract
Introduction: The product of heart rate and systolic blood pressure, termed as rate-pressure product (RPP), is a very 
reliable indicator of myocardial oxygen demand and is widely used clinically. There have been previous attempts to 
describe the relationship between RPP and the onset of pain in angina pectoris. The current study aimed to evaluate the 
association between RPP results and scan findings.
Materials and methods: In total, 497 patients with suspected coronary artery disease (CAD) underwent gated, single-
photon emission computed tomography (SPECT) imaging with dipyridamole, exercise, or dobutamine stress, and were 
included in this study. Baseline and maximum heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure 
(DBP), and electrocardiogram (ECG) results were recorded. The rate-pressure product (RPP) was calculated as the 
product of heart rate and systolic arterial pressure for both baseline and maximum measures. The difference between 
the RPP max and the basal RPP is known as the RPP reserve. Researchers also obtained semi-quantitative analyses of 
myocardial perfusion imaging (MPI), using gated software, demographic information, risk factors of CAD, and pretest 
likelihoods of CAD using nomograms.
Result: Four hundred and ninety-seven cases, including 426 patients with dipyridamole stress, 59 with exercise stress, and 
12 with dobutamine stress, underwent myocardial perfusion imaging. Scan results were positive in 194 (45.5%) and negative 
in 232 (54.5%) patients with dipyridamole stress. In patients with exercise stress, the scan was positive in 24 (40.7%) cases 
and negative in 35 (59.3%) cases. In dobutamine stressed patients, the scan was positive in 6 (50%) cases and negative 
in the 6 remaining cases. Dipyridamole stress resulted in a significant difference between HR at rest and at maximum 
(28.95 ± 24.53, p-value<0.0001), between systolic BP at rest and maximum (6.75 ± 12.50, p-value<0.0001) and between 
diastolic BP at rest and maximum (1.45 ± 5.80; p-value<0.0001). There was a significant correlation between sum stress 
scores (SSS) and reserved RPP (r= -0.12, p-value<0.001) which, in dipyridamole patients, was r=-0.18, p-value=0.0001). In 
addition, there was a significant association between reserved RPP and risk of CAD (p-value<0.001). In the patients with 
dipyridamole stress, the ejection fraction (EF) change (odds ratio =0.92; 95% CI: 0.86-0.98; p=0.01), reserve RPP (odds 
ratio =1.00; 95% CI: 1.00-1.00; p=0.04), risk of CAD (odds ratio =5.80; 95% CI: 3.21-10.50; p<0.0001) and age (odds ratio 
=0.94; 95% CI: 0.89-0.98; p=0.01) were associated significantly with MPI results, using multiple logistic regressions.
Conclusion. The study demonstrated that RPP is associated with MPI findings using gated SPECT imaging with dipyridamole 
stress. However, to confirm this preliminary result, further studies are mandatory.
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Coronary artery disease (CAD) results from an imbal-
ance between oxygen supply and the demands of the 
heart1-3. The need for oxygenated blood by the myocar-
dium relates to heart rate, blood pressure, left ventricular 
contractility, and left ventricular wall stress1,3-5. 
Myocardial oxygen consumption (MVO2) is a good indi-
cator of the response of coronary circulation to increased 
myocardial oxygen demand1,6,7. The coronary blood flow 
(CBF) shows a linear correlation with the level of 
MVO26,8,9. Thus, the determinants of MVO2 are also the 
determinants of CBF1,6. Direct measurement of MVO2 is 
difficult in routine clinical practice, but it can be easily 
calculated by indirect methods using Stroke work, Pick’s 
Principle, the tension time index, and rate pressure prod-
uct (RPP)1.
The product of heart rate and systolic blood pressure, 
termed as rate-pressure product (RPP), is a very reliable 
indicator of myocardial oxygen demand and it is widely 
used clinically, especially in anesthesiology and rehabili-
tation10-12. It is an easily measurable index, which corre-
lates well with MVO2 and defines the response of the 
coronary circulation to myocardial metabolic demands13. 
It is a good index of MVO2 in patients with ischemic 
heart disease13. In patients with coronary artery disease 
(CAD), the occurrence of ischemic events has been 
shown to be related closely to increases in the rate-pres-
sure product14.
In addition, this important measurement is calculated 
in routine nuclear medicine practice during myocardial 
perfusion imaging; however, there are few reports spe-
cifically investigating RPP in nuclear medicine. This pre-
liminary study was designed to evaluate the utility of 
RPP in the current practice of nuclear medicine.
Materials and methods
Participants. The study included 664 patients with 
known or suspected CAD referred for myocardial perfu-
sion imaging using gated 99mTc-MIBI SPECT between 
November 2007 and June 2009. Each patient filled out a 
questionnaire that included demographics and risk fac-
tors for CAD. Of them, 173 patients had insufficient 
data, and 24 had an arrhythmia during MPI implemen-
tation; therefore, 497 patients enrolled in this study. The 
risk factors for CAD include: (1) hypertension (systolic 
blood pressure ≥140 mmHg or diastolic blood pressure 
≥90 mmHg or receiving antihypertensive drugs); (2) 
fasting blood sugar (FBS) ≥126 mg/dl or receiving hypo-
glycemic agents; (3) dyslipidemia (low density lipopro-
tein [LDL] >130 mg/dl or high density lipoprotein 
[HDL] <35 mg/dl or triglyceride [TG] ≥200 mg/dl); (4) 
smoking; (5) positive familial history (myocardial infarc-
tion [MI] or sudden death before the age of 55 for males 
and 65 for females among first relatives); (6) body mass 
index ≥30 kg/m2. The pretest likelihood of CAD was esti-
mated by means of nomograms that correlated the pres-
ence of diabetes with age, the ratio of cholesterol to HDL, 
gender, and smoking15. In addition, an abnormal ECG 
was designated as a 0.1 mV horizontal or down-sloping 
ST segment depression of 80 msec after the J point.
The research complied with the Declaration of 
Helsinki and the Institutional Ethics Committee of 
Bushehr University of Medical Science approved the 
study; all patients gave written informed consent.
Study protocol
Dipyridamole technetium-99m sestamibi SPECT protocol. Over-
all, 426 patients fasted overnight and all cardiovascular med-
ications were discontinued at least two days before the study. 
An intravenous line of normal saline solution was connected 
to an antecubital vein, using a 20-gauge cannula. Dipyri-
damole (0.56 mg/kg) was infused over four minutes. Patients’ 
symptoms and a twelve-lead ECG were monitored continu-
ously. A dose of 740 MBq of 99mTc-sestamibi as a compact 
bolus was injected 4 minutes after the initiation of the infu-
sion. Sixty minutes later, the patients ate a fatty meal to accel-
erate hepatobiliary clearance of 99mTc-sestamibi, and 
imaging followed 90 minutes after the initial infusion of 
dipyridamole. The rest phase was performed the next day.
Technetium 99m sestamibi SPECT exercise protocol. After 
the same precautions as described for the dipyridamole test, 
59 patients exercised on a treadmill under a standard Bruce 
protocol. At the achieved peak heart rate (more than 85% of 
the age-predicted maximum heart rate), the appearance of 
typical angina, and/or positive exercise ECG findings, 740 
MBq of 99mTc-MIBI was injected as a compact bolus. The 
exercise test was considered positive if there was a horizon-
tal or down-sloping ST segment depression of more than 1 
mm for 80 microseconds after the J point. An intravenous 
line of normal saline solution was positioned in an antecu-
bital vein with a 20-gauge cannula. Imaging was performed 
15–30 minutes after the exercise. On the next day, 60 min-
utes after an injection of 740 MBq 99mTc-MIBI, the 
patients ate a fatty meal to accelerate the hepatobiliary 
clearance of 99mTc-MIBI. The resting gated SPECT was 
performed 90 minutes after the 99mTc-MIBI injection.
Dobutamine technetium 99m-sestamibi SPECT protocol. In 
12 patients, post IV infusion of sequentially increasing 
doses of dobutamine (starting at 10 µg/kg/min and reaching 
40 µg/kg/min), 740 MBq of 99mTc-MIBI was injected 
intravenously, and a myocardial perfusion scan SPECT was 
performed in the stress phase as a dipyridamole test. The 
rest phase was tested on the following day.
Acquisition and processing protocols. A double-headed 
SPECT scintillation camera (ADAC Genesys, Malpitas CA, 
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USA) was used to acquire 32 views over 180º using a step-
and-shoot method, progressing from 45º right anterior 
oblique to 45º left posterior oblique projections. A 20% 
symmetric energy window around the 140 keV Tc-99m 
photopeak and a low energy all-purpose (LEAP) collimator 
were applied, and the information was saved in 64 * 64 
matrices. Acquisition time was 30 seconds per projection 
during rest and stress studies and 8 frames per cycle were 
applied. An expert nuclear medicine specialist used the cine 
display of the rotating planar projections to evaluate sub-
diaphragmatic activities, attenuations, and patient motion 
to optimize the quality of the images. Processing was per-
formed using a two-dimensional Butterworth pre-filter and 
a ramp filter for back projection to transaxial tomographic 
images. The transaxial views were realigned along the ver-
tical long, horizontal, and short axes of the left ventricle. 
Acquisition parameters were identical for the rest and stress 
studies. For each patient, each of the three stress images 
was interpreted separately in comparison with the patient’s 
rest image.
Visual and semi-quantitative SPECT analysis. For assess-
ment, scans were divided into 20 segments, corresponding 
to the location of the territories of the various coronary 
arteries. A three-grade scale was used to evaluate the seg-
ments: normal perfusion, ischemic, and fixed segments. 
Ischemia was defined as the presence of a region with 
decreased or absent myocardial activity on exercise scans 
which improved on the rest stage images. A fixed segment 
was defined as a region of decreased or absent myocardial 
activity, both on exercise scans and on rest images.
In addition, gated short-axis images were processed 
using quantitative gated SPECT software (AutoQUANT; 
ADAC Laboratories, Maddison, WI, USA); the left ven-
tricular ejection fraction (LVEF) and the summed stress 
score (SSS) were automatically calculated.
Rate pressure product (RPP) measurement
At first, the baseline HR, SBP, DBP, and ECG results were 
recorded and blood pressure was measured in the left 
arm of subjects by an aneroid sphygmomanometer. The 
ECG and HR were constantly displayed on a monitor 
and were recorded on paper at one-minute intervals. The 
patient’s blood pressure was recorded every second min-
ute for each stress type.
The rate-pressure product (RPP) was calculated as the 
product of heart rate (beats per minutes) and systolic 
arterial pressure (mmHg) multiplied by 10-3.4-6 The 
peak-rate pressure product was calculated by multiply-
ing the maximum heart rate by the maximum systolic 
blood pressure attained for each stress type. It should be 
mentioned that peak HR in the dipyridamole group was 
defined as the highest HR during the observation period 
(before the administration of aminophylline, if that 
happened), since the effects of dipyridamole could 
remain relevant after the completion of the infusion.
Basal RPP is the product of the resting HR and the 
resting systolic blood pressure. The difference between 
the RPP max and the basal RPP is known as the RPP 
reserve.
Statistical analysis
Continuous variables were expressed as the mean ± SD, 
and categorical variables as absolute values and percent-
ages. Student’s t-test compared the mean difference of 
the continuous variables between two groups; the com-
parison of categorized variables between the two groups 
was performed using the Chi-squared test. Researchers 
used the Statistical Package for the Social Science (SPSS) 
version 18 (SPSS Inc., Chicago, IL, USA) to perform the 
statistical analysis. A p-value <0.05 was considered statis-
tically significant.
Results
The 497 test patients were comprised of 162 males 
(32.6%) and 335 females (67.4%). Four hundred and 
twenty-six patients underwent dipyridamole stress tests, 
59 exercise treadmill tests (ETT), and 12 dobutamine 
stress tests. The mean age of patients undertaking dipyr-
idamole tests was 58.80 ± 10.57 years (age range 22.00 - 
97.00); for the exercise group, it was 51.32 ± 7.99 years 
(age range 38 - 72 years), and for those undertaking 
dobutamine tests, it was 54.00 ± 15.09 years (age range 
25 - 72 years) (Table 1).
Dipyridamole patients had 34 positive ECG tests and 
392 negative ECGs (426 cases); exercise produced 9 posi-
tive ECGs and 50 negative ECGs (59 case) and dobu-
tamine patients had 3 positive ECGs and 9 negative 
ECGs (12 cases) (Table 1).
Scan results were positive in 194 (45.5%) patients 
and negative in 232 (54.5%) patients in the dipyrida-
mole group. In the exercise group, the scan results were 
positive in 24 (40.7%) cases and negative in 35 (59.3%) 
cases. In the dobutamine group, the scan results were 
positive in 6 cases (50%) and negative in 6 cases (50%) 
(Table 1).
The maximum and reserve RPP values in the patients 
with normal and abnormal MPI showed a significant 
difference only in the dipyridamole group (p-value=0.04 
and p-value=0.03). The ∆HR and the ∆SBP were also 
significant in the dipyridamole group between normal 
and abnormal MPI, while just the ∆HR was different in 
the exercise group (Table 2). In addition, neither was dif-
ferent in the dobutamine group, which may be due to the 
low number of cases in this subgroup (Table 2).
In the dipyridamole group, there was a significant dif-
ference between basal HR and maximum HR (∆HR) 
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Table 3. The distinction of heart rate and blood pressure changes in the patients with normal and abnormal MPI in the three groups
Type of MPI MPI result ∆HR P-value ∆sys. BP P-value
Dipyridamole Normal 30.97±24.98 0.06 7.92±14.23 0.01
 Abnormal 26.55±23.82 5.00±9.93  
Exercise Normal 68.91±17.68 0.01 34.19±109.93 0.51
 Abnormal 53.95±25.41 19.16±21.24  
Dobutamine Normal 56.00±22.37 0.54 10.00±12.64 0.24
 Abnormal 49.50±12.16 22.50±22.38  
MPI, myocardial perfusion imaging; HR, heart rate; sys.BP, systolic blood pressure; ∆, difference between rest and stress values.
(28.95 ± 24.53, p-value <0.0001), between basal and 
maximum systolic BP (∆SBP) ( 6.75 ± 12.50, p-value 
<0.0001) and between basal and maximum diastolic BP 
(∆DBP) ( 1.45 ± 5.80; p-value <0.0001); there was no 
significant difference between EF at rest and maximum 
(∆EF) ( -0.90 ± 9.82 %, p-value = 0.22) (Table 3).
In the exercise group, there was a significant differ-
ence between basal HR and maximum HR (∆HR) (60.28 
±23.76, p-value <0.0001), between basal and maximum 
systolic BP (∆SBP) (27.63 ± 83.44, p-value = 0.01), 
between basal and maximum diastolic BP (∆DBP) (4.35 
± 8.93; p-value <0.001), and between EF at rest and max-
imum (∆EF) (-4.00 ± 7.63, p-value = 0.03) (Table 3).
In the dobutamine group, there was a significant dif-
ference between basal HR and maximum HR (∆HR) 
(49.33 ±17.59, p-value <0.001), between basal and maxi-
mum systolic BP (∆SBP) (16.25 ± 17.98, p-value = 0.01), 
and between EF at rest and maximum (∆EF) (-7.57 ± 
6.72, p-value = 0.02); there was no significant difference 
between basal and maximum diastolic BP (∆DBP) (0.41 
± 6.55; p-value = 0.83) (Table 3).
There was a significant correlation between SSS and 
reserved RPP (r = -0.12, p-value <0.001) in all cases, but 
it was more pronounced in the dipyridamole group (r = 
-0.18, p-value <0.0001). In addition, there was a signifi-
cant association between reserved RPP and risk of CAD 
(p-value <0.001) in all patients.
In the patients with dipyridamole stress, the EF change 
(odds ratio = 0.92; 95% CI: 0.86 - 0.98; p=0.01), reserve 
RPP (odds ratio =1.00; 95% CI: 1.00 -1.00; p=0.04), risk 
of CAD (odds ratio =5.80; 95% CI: 3.21-10.50; p<0.0001) 
and age (odds ratio = 0.94; 95% CI: 0.89 - 0.98; p=0.01) 
were associated significantly with MPI results, using 
multiple logistic regressions. However, the reserve RPP 
did not show such an association with MPI results in the 
same analysis of the exercise and dobutamine groups 
(p-value >0.05).
On the other hand, multivariate linear analyses, 
adjusting for main clinical risk factors, revealed that 
age, SSS, risk of CAD, and sex were the independent 
Table 1. Patient characteristics
Age 57.79±10.69 years
Male/Female 162/335






Risk of CAD mild 282(56.74%)
 moderate 73(14.68%)
 high 81 (16.29%)
 very high 61(12.27%)
Chest pain typical 234/497(47.08%)
 atypical 212(42.65%)
 non-specific 51(10.26%)
IHD, ischemic heart disease; HLP, hyperlipidemia; HTN, hypertension; 
DM, diabetes mellitus; FM, familial history; CAD, coronary artery disease.
Table 2. The rate pressure product values in the patients with normal and abnormal MPI in the three groups
Type of MPI MPI result Base RPP P-value Maximum RPP P-value Reserve RPP P-value
Dipyridamole Normal 10.92±3.15 0.50 16.10±5.11 0.04 5.25±4.21 0.00
 Abnormal 10.71±3.14 14.78±4.72 4.07±3.81  
Exercise Normal 13.03±3.03 0.27 27.22±16.41 0.20 14.67±17.38 0.26
 Abnormal 12.17±2.56 22.66±6.93 10.49±6.01  
Dobutamine Normal 10.91±2.88 0.40 19.95±5.89 0.40 9.03±5.38 0.70
 Abnormal 12.22±2.30 22.21±2.58 9.98±2.46  
MPI, myocardial perfusion imaging; RPP, rate-pressure product.
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determinants for prediction of reserve RPP across different 
models in the dipyridamole group of patients (Table 4).
Discussion
This study showed that RPP could be a predictor of myo-
cardial ischemia in patients who underwent dipyridamole-
stress MPI. The percentage increase in RPP using 
dipyridamole stress was significantly more in patients 
without CAD compared to patients with CAD, indicating 
better coronary perfusion in the former cases. On the other 
hand, the smaller percentage increase in the RPP of patients 
with CAD suggests significant compromise of coronary 
perfusion and decreased left ventricular function.
As mentioned, the hemodynamic response to dipy-
ridamole is considered normal when it displays the 
effects of systemic vasodilatation, and HR increases as 
BP decreases16,17. The percentage increase in HR and SBP 
in dipyridamole stress was comparable in the two other 
study groups and the percentage increase in HR and SBP 
was significantly more in patients without CAD com-
pared to patients with CAD.
The current study also showed associations among 
RPP reserve, SSS, and pretest likelihood of CAD in all 
patients and in the dipyridamole group. A decrease in 
the basal RPP and an improvement in RPP max results 
produced higher RPP reserves - the difference between 
these two values.
The increased RPP reserve means that the heart is 
capable of producing more work before showing any 
signs of ischemia; the heart is taxed to a lesser degree for 
the same intensity of exercise, making the perceived exer-
tion lower for any given workload13.
Previous investigations regarding exercise have 
revealed that RPP is valid as a predictive value of MVO2 
during exercise in patients with ischemic heart disease18. 
Other studies have shown that angina is precipitated by 
an increase in the work of the myocardium, as measured 
by RPP, to a critical value that is essentially fixed in each 
patient19. Subsequently, the peak RPP is an accurate 
reflection of the myocardial O2 demand and workload. 
Reaching a high RPP without symptoms or evidence of 
severe ischemia suggests adequate left ventricular func-
tion. A low value of RPP reserve suggests significant lim-
itation of coronary perfusion and decreased left 
ventricular function, which lead to angina.
HR and SBP are the most important variables deter-
mining changes in myocardial oxygen consumption 
between rest and exercise19. As reported earlier, there 
were significant increases in SBP, HR, and RPP with exer-
cise, due to increases in sympathetic discharge1. HR, SBP, 
and RPP increase with increased workload on the heart 
to provide an adequate blood supply to the active myo-
cardium during exercise. In the current study, RPP 
increased progressively with exercise and attained the 
peak value of 22.66 ± 6.93 mmHg × beats/min × 10–3 in 
patients with CAD and 27.22 ± 16.41 mmHg × beats/
min × 10–3 in patients without CAD.
A previous study evaluated the association of RPP 
values with 37 individuals during exercise; 24 had 
ischemic heart disease (IHD) with a disease of 1, 2, or 3 
vessels, and 13 had non-significant lesions of 1 vessel 
(less than 75%) or no coronary heart disease (CHD) on 
angiograms of the coronary arteries18.
The researchers demonstrated that there was no dis-
tinction of RPP values between patients with CHD, with 
or without an ejection fraction less than 50%, or with or 
without disturbances of myocardial contractility, and 
normal individuals18. They mentioned that coronary 
vasoconstriction increased sympathetic tonus after exer-
cise and that this resulted from increasing thromboxane 
A2 having a potent vasoconstrictive and platelet-aggre-
gating effect, diminishing the anti-aggregatory effect of 
prostacyclin18. These researchers concluded that an 
excessive increase in the oxygen requirement of the myo-
cardium was not the sole pathogenic mechanism of 
ischemia in patients with CAD18.
In the current study, there was no significant differ-
ence in RPP values between patients with and without 
CAD in the dobutamine group.
In other studies, using positron emission tomography 
(PET), C-11–labeled palmitic acid has been used as a 
marker of oxidative metabolism20,21. The studies revealed 
that the clearance rate constant of [11C] acetate as an 
index of oxidative metabolism increased in relation to 
the increase in pressure-rate product during dobutamine 
Table 4. Multivariate linear analyses adjusting for main clinical 
risk factors for the prediction of reserve RPP across different 
models in the patients
Variable RRPP 
 β ρ R2
Model 1 0.039
 Age –0.19 0.01  
Model 2 0.065
 Age –0.18 0.01  
 SSS –0.16 0.04  
Model 3 0.091
 Age –0.26 0.00  
 SSS –0.26 0.00  
 Risk of CAD –0.20 0.03  
Model 4 0.115
 Age –0.26 0.00  
 SSS –0.31 0.00  
 Risk of CAD –0.21 0.03  
 Sex  0.16 0.04  
RRPP, reserve rate pressure product; SSS, sum stress score; CAD, coro-
nary artery disease
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infusion in both left ventricular and right ventricular 
myocardium. They concluded that it could be used as a 
safe and valuable alternative for estimating the increase 
in oxidative metabolism in patients with various cardiac 
disorders22. In addition, Henes et al. showed an increase 
in Kmono in proportion to the increase in the pressure-
rate product23.
The significant difference in RPP, including max and 
reserve RPP, between patients with and without CAD 
only in the dipyridamole group remains unexplained. It 
is significant that RPP equals HR multiplied by BP and 
that BP is calculated by multiplying cardiac output (CO) 
by vascular resistance (VR)24. In addition, cardiac output 
(Q) equals stroke volume (SV) × HR25; therefore, RPP 
equals SV*VR*HR2. As a note to this equation, all three 
items are related to sympathetic nervous system activity 
and decreased parasympathetic nervous system activity. 
On the other hand, the principle in exercise and dobu-
tamine stresses is based on sympathetic over-activity, 
which is observed in the patients with and without coro-
nary disease (CAD), but dipyridamole stress is not 
affected by this issue. This hypothesis may illustrate the 
predictable role of RPP being limited to the dipyrida-
mole MPI in the current study.
In total, the results may suggest that the measurement 
of RPP in response to physiological stress following 
dipyridamole during MPI implementation, and accom-
panied by other risk factors, signs, and symptoms, can 
help to detect CAD more accurately.
The current preliminary study had some shortcom-
ings. The major limitation was the small sample size in 
the exercise and dobutamine stress MPI groups. The 
other limitation was the absence of coronary angiogra-
phy as a gold standard test, since most of the patients 
were females and the sensitivity of diagnosing significant 
CAD utilizing MPI is low in females. Both of these limi-
tations may have influenced the results of this study; 
therefore, these preliminary results should be validated 
in a larger, well-designed study.
Conclusion
The study demonstrated that RPP is associated with MPI 
findings using gated SPECT imaging with dipyridamole 
stress. However, to confirm this preliminary result, fur-
ther studies are mandatory.
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